In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.
QTRAP / Triple Quad
QTRAP / Triple Quad systems
Unlock the benefits of nominal mass spectrometry for NPS analysis
The development of analytical methods for the detection and quantitation of drugs and metabolites in a range of biological matrices is a challenging process. Forensic toxicology labs need a reproducible and reliable methodology to ensure the robustness of the data and the quality of the results. They also need robust and sensitive instrumentation that can detect drugs at trace levels with high specificity, especially when it comes to novel psychoactive substances (NPS), which can be difficult to monitor and control.
Metabolite identification and peace of mind
Managing metabolite identification (Met ID) studies is challenging, so what is at the top of your priority list as you plan the year ahead? Ensuring you have the data needed to manage product safety, meeting deadlines, staff recruitment and training, maintaining compliance, capital expenses, or something else?
calibration using sum of peak areas vs concentration
Hi,
Source optimization
Hello. I am setting up a new development method for analyzing toxic chemicals.
Overcoming N-nitrosamine analysis challenges with mass spectrometry and chromatography solutions
N-nitrosamine analysis has raised significant concerns in the pharmaceutical industry since 2018, when these potential carcinogens were found in several angiotensin II receptor blockers (sartans). Subsequent discoveries in ranitidine and some slow-release metformin medications prompted widespread product recalls. The industry has implemented stricter manufacturing requirements and intensified efforts to evaluate and control N-nitrosamine contamination. To meet stringent regulatory requirements, it is essential to develop effective chromatography and mass spectrometry (MS) methods for N-nitrosamine analysis. This blog addresses the challenges associated with detecting N-nitrosodimethylamine (NDMA) in metformin drug products.
Selecting the right system for bioanalytical quantitation
Investing in a new LC-MS system is not an easy decision, especially if you have a range of analytical requirements in your laboratory. This blog is part of a series intended to help you choose the right system for your pharmaceutical research and development needs.
Reporting only unknown samples containing a specific sample ID prefix (in this case Sample ID prefix = PHT)
I am using Multiquant software and I am trying to create a report to pull data on specific sample from a large run.
N-Methyl Pyrollidone
I am in the process of analyzing nitrosamines using QTRAP. One of the difficulties in my sample preparation would be using NMP as solvent to dissolve the material. Is it safe to inject approximately 10ul of NMP is QTRAP??
Standard peaks are noisy
I am Using Sciex Qtrap 4500 for quantification of nitrosamines (NDMA&NDBA). I am facing issue with higher baseline intensity. When developed the method in APCI the basline was at about 5e4. but now even after cleaning the source (i.e. Changed capillary to new, Curtain plate & Corona needle cleaning, given blank injection overnight ), my base line decreased from 1e6 to 4 e5, but settled at 4 e5 from past 24 hours. can you suggest me how decrease my baseline intensity further to below 1e5. My standard peaks are like noise now.